Metabolic Adaptation of Neutrophils in Cystic Fibrosis Airways Involves Distinct Shifts in Nutrient Transporter Expression

Julie Laval, Jawida Touhami, Leonore A. Herzenberg, Carol Conrad, Naomi Taylor, Jean-Luc Battini, Marc Sitbon and Rabindra Tirouvanziam

*J Immunol* 2013; 190:6043-6050; Prepublished online 20 May 2013; doi: 10.4049/jimmunol.1201755
http://www.jimmunol.org/content/190/12/6043

Supplementary Material  http://www.jimmunol.org/content/suppl/2013/05/21/jimmunol.1201755.DC1

References  This article cites 48 articles, 21 of which you can access for free at: http://www.jimmunol.org/content/190/12/6043.full#ref-list-1

Subscription  Information about subscribing to *The Journal of Immunology* is online at: http://jimmunol.org/subscription

Permissions  Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts  Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts
Metabolic Adaptation of Neutrophils in Cystic Fibrosis Airways Involves Distinct Shifts in Nutrient Transporter Expression

Julie Laval,†,‡,§ Jawida Touhami,¶,†,‡ Leonore A. Herzenberg,*, Carol Conrad,¶ Naomi Taylor,§,¶ Jean-Luc Battini,*,§ Marc Sitbon,§,¶ and Rabindra Tirouvanziam*,†,§

Inflammatory conditions can profoundly alter human neutrophils, a leukocyte subset generally viewed as terminally differentiated and catabolic. In cystic fibrosis (CF) patients, neutrophils recruited to CF airways show active exocytosis and sustained phosphorylation of prosurvival, metabolic pathways. Because the CF airway lumen is also characterized by high levels of free glucose and amino acids, we compared surface expression of Glut1 (glucose) and ASCT2 (neutral amino acids) transporters, as well as that of Pit1 and Pit2 (inorganic phosphate transporters), in blood and airway neutrophils, using specific retroviral envelope-derived ligands. Neither nutrient transporter expression nor glucose uptake was altered on blood neutrophils from CF patients compared with healthy controls. Notably, however, airway neutrophils of CF patients had higher levels of Pit1 and Glut1 and increased glucose uptake compared with their blood counterparts. Based on primary granule exocytosis and scatter profiles, CF airway neutrophils could be divided into two subsets, with one of the subsets characterized by more salient increases in Glut1, ASCT2, Pit1, and Pit2 expression. Moreover, in vitro exocytosis assays of blood neutrophils suggest that surface nutrient transporter expression is not directly associated with primary (or secondary) granule exocytosis. Although expression of nutrient transporters on CF blood or airway neutrophils was not altered by genotype, age, gender, or Pseudomonas aeruginosa infection, oral steroid treatment decreased Glut1 and Pit1 levels in blood neutrophils. Thus, neutrophils recruited from blood into the CF airway lumen display augmented cell surface nutrient transporter expression and glucose uptake, consistent with metabolic adaptation. The Journal of Immunology, 2013, 190: 6043–6050.

Neutrophils provide a critical defense against infection (1) by phagocytosis of microorganisms or extracellular killing via exocytosis of toxic granule effectors, sometimes in combination with the formation of extracellular traps (2). Blood neutrophils are commonly viewed as terminally differentiated effector cells with very limited capacity to stray away from a default program of activation/apoptosis, which they generally follow upon leaving the bone marrow. However, recent evidence suggests that profound changes in neutrophil survival and function can occur upon their recruitment from blood into diseased organs, as a result of permissive/stimulatory environmental conditions therein (3).

In the fatal disease cystic fibrosis (CF), we previously demonstrated that neutrophils recruited from blood into the diseased airway environment undergo marked functional changes (4). In particular, CF airway neutrophils undergo active exocytosis of primary granules, leading to massive release of enzymes (e.g., elastase, myeloperoxidase) that damage the airway tissue and perpetuate inflammation. More intriguingly, we also observed that CF airway neutrophils express high levels of markers conventionally found on long-lived APCs, including class II MHC, the costimulatory molecule CD80, and the chemoattractant receptor of Th2 cells (CD294), all of which suggest profound reprogramming (4).

CF airway neutrophils also undergo strong activation of CREB and mTOR prosurvival pathways (5). The CREB pathway is commonly induced in stress responses, as expected in the inflammatory environment of CF airways (6). However, the mTOR pathway is the main anabolic switch in eukaryotes, as well as to extracellular nutrients, notably glucose (7) and amino acids (8). Both glucose (9) and amino acids (10) tend to accumulate in CF airway fluid as the result of an apparent failure of the epithelium, lacking functional CFTR protein, to transport these anabolic nutrients (11–13). Additionally, CF airway fluid is enriched in breakdown products of phosphonucleotides (14), which fuel cellular energy production.
To investigate the process of metabolic adaptation by neutrophils recruited to CF airways, we used novel retroviral envelope glycoprotein (Env)-derived ligands to preserve leukocytes in their native state and stored at 80˚C until use. RNA isolation and genomic DNA removal were performed using RNeasy plus columns (QIAGEN), and extracts were stored at −80˚C until use.

**Cell surface assessment of Glut1, ASC2, Pit1, and Pit2 nutrient transporters**

Receptor-binding domains (RBDs) of gamma- and deltaretroviruses Env specifically interact with their cell surface receptor, all of which were shown to be metabolite transporters (24–27). In this study, we derived RBD ligands, as previously described (15), comprising the sequence encoding the (i) 178–185 aa of the signal peptide with the corresponding RBD of the (ii) 222 N-terminal amino acids of the RD114 (feline endogenous retrovirus) Env, which is a ligand for Pit2 (another inorganic phosphate transporter); (iii) 245 aminoterminal amino acids of the amphotropic murine leukemia virus (AMLV) Env, which is a ligand for Pit1 (inorganic phosphate transporter); and (iv) 27–29 aa of the human T cell leukemia virus type 2 (HTLV) Env, which is a ligand for Glut1 (sodium/dehydroascorbic acid transporter). For analysis of nutrient transporter expression and vigilin and LC3 expression, uptake, exocytosis, and cell sorting/quantitative RT-PCR assays. For analysis of nutrient transporter expression and vigilin and LC3 expression, blood and airway leukocytes were fixed in Phosflow Lyse/Fix Buffer (BD Biosciences) to preserve leukocytes in their native state and stored at 80˚C until use.

**Flow cytometric analysis of nutrient transporter expression**

Fixed frozen blood and airway cell samples were thawed, washed with PBS-EDTA, and surface stained at 37˚C with two combinations of two RBD ligands: HTLV-RBD EGFP (Glut1)/KoRV-RBD mFc (Pit1) or RD114-RBD mFc (ASC2)/AMLV-RBD rFc (Pit2). Although the HTLV-RBD EGFP ligand is inherently fluorescent, the other RBD ligands were used in a combination with fluorescently labeled Abs against mouse or rabbit IgG Fc (Life Sciences). Samples were also stained with chola toxin B (Life Sciences); after a wash in PBS-EDTA and permeabilization with Perm I buffer (BD Biosciences), they were stained with the DNA-binding probe DRAQ5 (Life Sciences). The combination of cholera toxin B and DRAQ5 enables robust gating of live neutrophils from blood and airway samples (30), as illustrated in Supplemental Fig. 1A. Control stainings combined anti-mFc or -rFc with cholera toxin B and DRAQ5, in the absence of RBD ligands. After a final wash in Perm I buffer at room temperature, samples were analyzed on a LSR II flow cytometer (BD Biosciences), and expression of nutrient transporters was determined after fluorescence compensation (FlowJo software; TreeStar) (30). Data are reported as differential median fluorescence intensity (delta MFI) between the specific RBD staining and the corresponding background control for each individual sample.

**Glucose-uptake assays**

Glucose uptake was analyzed using the fluorescent glucose analog 2-N-[7-nitrobenz-2-oxa-1,3-diazol-4-yl]amino]-6-deoxyglucose (2-NBDG; Cayman Chemical). Blood was treated with ammonium chloride to lyse RBCs, after which blood leukocytes were spun down and washed with PBS-EDTA. Leukocytes from blood and airway were pretreated at 4˚C with Live/Dead (Life Sciences) and anti-CD16 and -CD63 (both from BioLegend) to enable gating of live neutrophils (4). After a wash with PBS-EDTA, leukocytes were equilibrated in serum-free RPMI 1640 (Cellgro) at 4˚C for ≥45 min. Leukocytes were then washed and resuspended in PBS, and 2.5 × 10^5 leukocytes were incubated for 1 min at 37˚C with 2-NBDG at 100 µM (31). After a wash in PBS-EDTA, samples were analyzed on a LSR II flow cytometer, as above, and uptake was determined as delta MFI between 2-NBDG–stained and unstained conditions for each sample.

**Cell sorting and quantitative RT-PCR to assess nutrient transporter transcript levels**

Blood was treated with ammonium chloride to lyse RBCs and then spun down and washed with PBS-EDTA. Blood and airway leukocytes (1 × 10^6) were stained at 4˚C with Live/Dead, anti-CD15 (BioLegend), anti-CD16 (BioLegend), and anti-CD63 (BD Biosciences) Abs to enable gating of live neutrophils (4). After a wash with PBS-EDTA, blood and airway neutrophils were sorted with a FACS Jazz Cell Sorter using BD FACS Software (BD Biosciences). Nucleic acids from sorted blood and airway neutrophils were extracted using the Qiashredder kit (QIAGEN), and extracts were stored at −80˚C until use. RNA isolation and genomic DNA removal were performed using RNeasy plus columns (QIAGEN), and the quality/quantity of RNA were determined using the ND-1000 spectrophotometer (NanoDrop Technologies). First-strand cDNA synthesis was carried out using Superscript II reverse transcriptase (Invitrogen), according to the manufacturer’s instructions. Specific paired primers (forward/reverse) were used to determine the levels of the following transcripts—Glut1 (5'-TGCTGATGATGAACTGTG-3'; 5'-GATAGGATGGCCGAC-3'), Pit1 (5'-CAACGTGTAATGAAAGAGG-3'; 5'-TGACCCTTGACTGAACGTG-3'), and Pit2 (5'-TCTCATGGSGGAAGTTAGT-3'; 5'-TCTGGCACTGTTGAAACTT-3')—and β-actin (ACTB) as the reference gene (32). Transcripts were amplified and measured using the ABI 7500 thermocycler with SYBR Select Master Mix (Life Sciences), according to the manufacturer’s instructions. Transcript levels were quantified relative to ACTB in each sample. Efficiency of RNA recovery per number of cells and number of cycles required for ACTB RNA amplification were equivalent for all sample categories (B, A1 and A2 sorted neutrophils), indicative of an absence of particular RNA degradation for the different subsets of neutrophils.

**Exocytosis and nutrient transporter surface expression assays**

Exocytosis (secondary and primary granules) and nutrient transporter surface expression were analyzed on blood neutrophils upon incubation...
with latrunculin B (LB) combined with the bacterial formyl peptide iMLF; LB and iMLF (both from Sigma-Aldrich) were prepared as 1000× frozen stocks in DMSO and diluted immediately prior to use. Blood was washed and resuspended in medium (serum-free RPMI 1640) at 5 × 10⁶/ml and incubated with LB (1.25 μM) for 5 min at 37°C, followed by iMLF (5 μM) for 10 min at 37°C. In these conditions, primary and secondary neutrophil granules (and tertiary granules) are exocytosed to a large extent (33). Incubations were stopped by washing the cells with ice-cold PBS-EDTA and transferring tubes on ice. Samples were then stained at 4°C with Live/Dead and cholera toxin B to enable live neutrophil gating, as well as anti-CD66b (BioLegend) and anti-CD63 (BD Biosciences) to measure secondary and primary granule release, respectively (4). Samples were then fixed in Phosflow Lyse/Fix Buffer to preserve stained leukocytes, stored and resuspended in medium (serum-free RPMI 1640) at 5 × 10⁶/ml and incubated with LB and fMLF (both from Sigma-Aldrich) were prepared as 1000× frozen stocks in DMSO and diluted immediately prior to use. Blood was washed and resuspended in medium (serum-free RPMI 1640) at 5 × 10⁶/ml and incubated with LB (1.25 μM) for 5 min at 37°C, followed by iMLF (5 μM) for 10 min at 37°C. In these conditions, primary and secondary neutrophil granules (and tertiary granules) are exocytosed to a large extent (33). Incubations were stopped by washing the cells with ice-cold PBS-EDTA and transferring tubes on ice. Samples were then stained at 4°C with Live/Dead and cholera toxin B to enable live neutrophil gating, as well as anti-CD66b (BioLegend) and anti-CD63 (BD Biosciences) to measure secondary and primary granule release, respectively (4). Samples were then fixed in Phosflow Lyse/Fix Buffer to preserve stained leukocytes, stored and thawed for batch staining with RBD probes and analysis of nutrient transporter expression, as described above.

**Multispectral imaging flow cytometric analysis of vigilin and LC3**

Fixed and frozen blood and airway cell samples were thawed, washed with PBS-EDTA, permeabilized with Perm I buffer (BD Biosciences), and stained with DRAQ5 and Abs directed against the nucleic acid–binding protein vigilin (Santa Cruz Biotechnology) and the autophagolysosome protein LC3 (MBL). The combination of LC3 and DRAQ5 also enables a robust gating of live neutrophils from blood and airway samples, as illustrated in Supplemental Fig. 1B. After a final wash in Perm I buffer, samples were analyzed on an ImageStreamX system (Amnis), and expression and localization (nuclear versus cytoplasmic) of vigilin and LC3 were quantified (IDEAS software) after fluorescence compensation (30, 34).

**FIGURE 1.** Detection of nutrient transporter expression by RBD-derived ligands. CHO cells were transduced with either an empty LXSN vector or an LXSN vector coding for the human ASCT2 (A), PiT1 (B), or PiT2 (C) transporter. Control- and transporter-transduced cells were then stained with cognate RD114-, KoRV-, and AMLV-RBD ligands. Data are presented for negative controls (open gray graphs) and background controls (transporter-transduced cells stained with secondary Ab alone, filled gray graphs), as well as for control- and transporter-transduced cells stained with the specific RBD (open and filled black graphs).

**Statistical analysis**

Statistical analyses of flow and image cytometry datasets were performed using the JMP9 software (SAS Institute). Nonparametric statistics were used throughout the study, because flow and image cytometry data are generally not distributed normally. Differences were assessed using paired statistics (Wilcoxon signed-rank test) when comparing distributions between blood and airway neutrophils and unpaired statistics (Wilcoxon rank-sum test) when comparing data between groups (e.g., CF versus HC, treatment with given medications, male versus female, presence or absence of given bacterial infections, and genotype). Correlations between flow and image cytometry data and continuous demographic data (age) were assessed by the nonparametric Spearman test. Differences were considered significant at *p* < 0.05. When appropriate, Bonferroni corrections were applied according to the number of simultaneous outcome measures for each set of experiments.

**Results**

**Novel retroviral Env ligands specifically bind to the ASCT2, PiT1, and PiT2 cell surface nutrient transporters**

We demonstrated previously that the RBD from HTLV was a specific ligand for the glucose/dehydroascorbic acid transporter Glut1 (15, 28, 29, 35). Based on previously established binding specificities for the Env of RD114 (36), KoRV (37), and AMLV (24) for the human neutral amino acid transporter ASCT2 and inorganic phosphate transporters PiT1 and PiT2, respectively, we developed specific RBD ligands for each of these three human nutrient transporters. Env-derived RBD ligands for ASCT2 (Fig. 1A), PiT1 (Fig. 1B), and PiT2 (Fig. 1C) specifically stained CHO cells transduced with the corresponding human nutrient transporter. In contrast, no significant RBD ligand labeling was observed when CHO cells were transduced with an empty vector (negative control), confirming that none of the three corresponding Envs recognizes the endogenous hamster nutrient transporters (27). Additionally, there was no significant RBD ligand staining of CHO cells transduced with a noncorresponding human transporter, confirming the ligand-to-transporter specificity.

**Neutrophils recruited to CF airways modulate nutrient transporter expression and glucose uptake**

A hallmark of airway neutrophils in CF patients is a robust activation of the anabolic mTOR pathway (5), which responds to ex-
tracellular metabolites, such as glucose and amino acids, and induces ATP production (7). Hence, we investigated the expression of glucose, amino acid, and phosphate transporters on blood and airway neutrophils from CF patients. Staining with RBD ligands revealed significant expression of Glut1, ASCT2, PiT1, and PiT2 on neutrophils from both compartments (Fig. 2). Comparison of blood neutrophils from HC (n = 6) and CF (n = 6) subjects showed no significant difference in nutrient transporter expression (Fig. 3A). However, comparison of paired blood/airway samples from CF patients (n = 12) showed a marked upregulation of Glut1 and PiT1 on airway neutrophils compared with blood neutrophils (1.81- and 1.77-fold, respectively, Fig. 3B, Table I), whereas ASCT2 and PiT2 expression profiles appeared unchanged. We then assessed glucose uptake by blood neutrophils and airway neutrophils using the fluorescent d-glucose analog 2-NBDG (Fig. 4). Although glucose uptake was similar in HC and CF blood neutrophils, it was markedly increased in CF airway neutrophils. Thus, differences in baseline surface Glut1 levels between CF blood and airway neutrophils (Fig. 3B) translated into differences in glucose uptake (Fig. 4).

**CF airway neutrophil subsets display distinct nutrient transporter surface expression profiles**

We showed previously that CF airway neutrophils can be split into two distinct subsets, designated as A1 and A2, based on low and high levels of exocytosis of toxic primary granules (and reflected by scatter properties), respectively (4). We found that these subsets also differed in their expression of nutrient transporters (Fig. 5). The A2 subset, which presented with higher levels of exocytic toxic granules according to scatter profiles (Supplemental Fig. 1), showed higher levels of Glut1 (1.29-fold, Table I) and more markedly increased levels of PiT1 (4.15-fold), PiT2 (3.59-fold), and ASCT2 (2.45-fold) compared with the A1 subset (Fig. 5, Table I). Although Glut1 was uniformly higher on airway neutrophils compared with blood neutrophils, regardless of the subset considered (A, A1, or A2), other nutrient transporters showed more complex patterns of modulation (Table I). Compared with blood neutrophils, ASCT2 expression was significantly lower on the A1 subset but was higher on A2 neutrophils (0.46- and 1.28-fold, respectively). This pattern was similar to that observed for PiT2 on airway neutrophils compared with blood neutrophils, with lower and higher expression on A1 and A2 neutrophils, respectively (0.38- and 1.30-fold, respectively). Thus, cell surface nutrient transporters in neutrophils that migrated from blood to the airways have patterns that distinguished the A1 and A2 neutrophil subsets. When assessing levels of Glut1, PiT1, and PiT2 transcripts in sorted blood (Supplemental Fig. 2), A1, and A2 neutrophil subsets, we found equivalent RNA recovery and actin RNA amplification, but no discernable increase in the transporter RNAs, despite increased surface expression. Rather, we noted a tendency for lower nutrient transporter transcript levels in airway versus blood neutrophils. Therefore, differences in transporter surface level expression are not reflected by synchronous modulation of the cognate transcripts.

**Table I. Comparative expression of nutrient transporters, vigilin (% cytoplasmic), and LC3 in CF blood and airway neutrophils**

<table>
<thead>
<tr>
<th>Marker</th>
<th>A Versus B</th>
<th>A1 Versus B</th>
<th>A2 Versus B</th>
<th>A2 Versus A1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glut1</td>
<td>1.81</td>
<td>1.37</td>
<td>1.80</td>
<td>1.29</td>
</tr>
<tr>
<td></td>
<td>&lt;10^{-3}</td>
<td>0.032</td>
<td>&lt;10^{-3}</td>
<td>0.002</td>
</tr>
<tr>
<td>ASCT2</td>
<td>1.09</td>
<td>0.46</td>
<td>1.28</td>
<td>2.45</td>
</tr>
<tr>
<td></td>
<td>0.584</td>
<td>0.011</td>
<td>0.17</td>
<td>&lt;10^{-3}</td>
</tr>
<tr>
<td>PiT1</td>
<td>1.77</td>
<td>0.64</td>
<td>2.24</td>
<td>4.15</td>
</tr>
<tr>
<td></td>
<td>0.002</td>
<td>0.190</td>
<td>&lt;10^{-3}</td>
<td>&lt;10^{-3}</td>
</tr>
<tr>
<td>PiT2</td>
<td>1.08</td>
<td>0.38</td>
<td>1.30</td>
<td>3.59</td>
</tr>
<tr>
<td></td>
<td>0.396</td>
<td>0.011</td>
<td>0.038</td>
<td>&lt;10^{-3}</td>
</tr>
<tr>
<td>Vigilin (%) cytoplasmic</td>
<td>5.68</td>
<td>7.58</td>
<td>4.89</td>
<td>0.93</td>
</tr>
<tr>
<td></td>
<td>0.001</td>
<td>0.001</td>
<td>0.001</td>
<td>0.097</td>
</tr>
<tr>
<td>LC3</td>
<td>1.82</td>
<td>0.92</td>
<td>2.18</td>
<td>2.10</td>
</tr>
<tr>
<td></td>
<td>&lt;10^{-3}</td>
<td>0.335</td>
<td>&lt;10^{-3}</td>
<td>&lt;10^{-4}</td>
</tr>
</tbody>
</table>

Fold differences in the expression of the indicated marker between total (A) or the A1 and A2 subsets of airway neutrophils over blood neutrophils (B) and A2 subset over A1 subset of airway neutrophils.

The p values provided are for paired analyses.
Oral steroids modulate Glut1 and PiT2 expression in CF blood neutrophils

Oral steroids (OSs) are powerful inhibitors of inflammation, often used to curb acute symptoms of inflammatory airway disease in CF (6), and inhibition of Glut1 expression and its membrane localization are among the multiple parameters altered by OS treatment (38). Consistent with this mode of action, we observed that OS treatment significantly decreased Glut1, as well as PiT2, expression on CF blood neutrophils (Fig. 6). OS treatment did not significantly affect the upregulation of Glut1 expression on airway neutrophils. However, OS treatment significantly increased the proportion of the A2 subset, which expressed higher levels of PiT2 transporter than did the A1 subset (3.59-fold, Table I), thus increasing PiT2 expression among total CF airway neutrophils (A subset) in OS-treated versus untreated patients. No significant change was observed in either ASCT2 or PiT1 surface expression on blood and airway neutrophils upon OS treatment. Unlike OS treatment, other common modifiers of CF airway disease (genotype, age, gender, or Pseudomonas aeruginosa infection) did not affect nutrient transporter expression (data not shown).

Increased surface expression of nutrient transporters is not due to exocytosis of secondary or primary granules

Compared with blood neutrophils, the A1 subset of CF airway neutrophils is characterized by a marked exocytosis of secondary granules (high CD66b with low CD63 surface expression), whereas the A2 subset is characterized by a marked exocytosis of both secondary and primary granules (high CD66b and CD63 surface expression) (4, 5). Because both subsets showed significant changes in nutrient transporter expression, we tested whether in vitro neutrophil activation and induction of granule exocytosis could alter surface expression of nutrient transporters. As previously reported (33), efficient secondary and primary granule exocytosis was triggered by the combined treatment with LB and fMLF and evidenced by marked increases in the CD66b and CD63 surface markers (5.66–6.87-fold and 23.74–29.4-fold, respectively, Supplemental Table II). In contrast, upon LB+fMLF treatment, nutrient transporter levels in HC and CF neutrophils remained within a range (0.61–1.67-fold) of those observed in control conditions. This range was markedly lower than that observed in vivo for the A2 subset, in which nutrient transporter expression ranged from 1.29- to 4.15-fold higher than in blood neutrophils (Table I). Of note, short-term incubation (10 min) of CF and HC blood neutrophils in CF airway fluid (cell- and bacteria-free) promoted changes in nutrient transporter expression that ranged from 0.96- to 1.5-fold (data not shown) lower than those observed for A2 cells in vivo.

Thus Glut1, ASCT2, PiT1, and PiT2 are not components of neutrophil secondary and primary granules, and changes in their cell surface expression cannot be recapitulated by exocytosis of these granules or exposure to CF airway fluid in vitro.
Recruitment of neutrophils to CF airways is associated with altered intracellular expression of the nucleic acid–binding protein vigilin and the autophagolysosome marker LC3

Vigilin is an RNA-binding protein with nuclear and cytoplasmic localizations, the latter being linked to anabolic activity in the form of increased RNA translation (17–19). Recent evidence from our group (J. Laval, M. Makam, D. Diaz, M. Preininger, M. Miglianico, L.A. Herzenberg, and R. Tirouvanziam, manuscript in preparation) and other investigators (39) suggests that CF airway neutrophils are transcriptionally and translationally active. In this study, we used image cytometry to monitor vigilin compartmentalization and observed a nuclear localization in CF blood neutrophils, although with a significant cytoplasmic translocation in airway neutrophils (Fig. 7). This translocation occurred in both the A1 and A2 subsets of airway neutrophils (7.58- and 4.89-fold compared with blood, Table I). Remarkably, expression of the catabolic protein LC3 (20–23) was increased markedly in the A2 subset of airway neutrophils (Fig. 7), but it was essentially unchanged in the A1 subset (2.1-fold compared with A1, Table I). Although vigilin and LC3 proteins could both be detected in the cytoplasm of CF airway neutrophils, they did not appear to colocalize (Fig. 7A). Taken together, our results suggest a complex process of neutrophil adaptation to the CF airway environment (Fig. 8).

Discussion

In this study, we demonstrate marked changes in glucose, amino acid, and phosphate transporters among subset of CF airway neutrophils. Using imaging flow cytometry, we further show that CF airway neutrophils express higher cytoplasmic levels of vigilin and LC3 compared with their blood counterparts, with significant differences among subsets for the latter. Together with our previous observation of sustained mTOR and CREB pathway activation in CF airway neutrophils (4, 5), this study suggests that neutrophils undergo significant metabolic adaptation as they are recruited to CF airways.

Under the nutrient-rich conditions provided by the CF airway milieu (9, 11, 12, 14), environmental strains of autotrophic bacteria acquired by patients overcome the many negative aspects of this hypoxic and antimicrobial-, protease-, and oxidant-laden environment to thrive and undergo autotrophic adaptation over time (10). Hence, the CF airway milieu exerts significant selective pressure on incoming bacteria, in large part through metabolic routes. Our results support the idea that inflammatory neutrophils recruited to the metabolically permissive CF airway milieu also undergo a metabolic adaptation.

The significant increase in Glut1 surface expression and glucose uptake detected in airway neutrophils compared with blood neutrophils supports the notion that these cells are able to use the high amount of glucose in the CF extracellular milieu (9). This is consistent with our previous data on the immediate activation of the glucose-sensitive mTOR pathway in neutrophils recruited to CF airways (5). Studies by other groups clearly established that neutrophils are avid consumers of glucose (40) and that the up-regulation of surface Glut1 expression is associated with neutrophil activation upon exposure to inflammatory conditions (41). A similar increase in glucose-dependent metabolism is seen in other activated leukocyte subsets, notably T and B cells (29, 42–45). In contrast with Glut1, expression of the amino acid transporter ASCT2 is not uniformly increased on CF airway neutrophils (decreased on A1 and increased on A2 neutrophils compared with blood neutrophils, respectively). Because ASCT2 is required for sustained branched amino acid–dependent mTOR activation in anabolic cells (8), our findings suggest that, among CF airway neutrophils, glucose-driven and amino acid–driven anabolic activities may be regulated independently. The absence of a marked difference in nutrient transporter expression between CF and HC neutrophils in blood suggests that, although chronic inflammation...
in CF patients may impact on the metabolism of circulating neutrophils, active recruitment to the airways seems to be required to fully promote anabolic adaptation.

The RNA-binding protein vigilin undergoes a major relocalization from the nucleus to the cytoplasm upon neutrophil recruitment from blood into CF airways. Cytoplasmic vigilin plays a key role in mRNA stabilization and positively regulates translation, notably in response to stress (17–19, 46). Interestingly, we observed that CF airway neutrophils undergo marked changes in their transcriptional profile compared with CF blood neutrophils (Laval et al., manuscript in preparation), consistent with reprogramming (3, 39). Thus, the cytoplasmic relocalization of vigilin detected in all airway neutrophils (A1 and A2 subsets) is consistent with the notion that neutrophils are primed for anabolic activation following their entry into CF airways. In contrast, the increase in LC3 expression occurs only in A2 cells compared with blood neutrophils. This result is consistent with our observations of a major shift in primary granule exocytosis in the A2 subset (4) and with the recently proposed role for the LC3 protein in granulocyte exocytosis (21). Alternatively, the LC3 protein may be involved in other catabolic functions in these cells, including LC3-associated phagocytosis or even conventional autophagic activity (20, 22, 23).

Interestingly, conditions inducing primary and secondary granule exocytosis, as produced by LB+HMLF treatment, did not induce nutrient transporter surface expression in the range observed in vivo. The lack of an obvious association between surface CD66b and CD63 and Glut1, ASCT2, PiT1, and PiT2 expression upon in vitro exocytosis is consistent with proteomic data, which did not identify nutrient transporters, such as Glut1, ASCT2, PiT1, or PiT2, in secondary and primary granules (47). Thus, these four nutrient transporters likely originate from other neutrophil compartments that are also subject to membrane mobilization. Rather than exocytosis processes per se, it is more likely that transepithelial migration, a process that induces strong signaling loops in migratory neutrophils and the surrounding tissue (48–50) and that was not reproduced in our in vitro activation assay, played a role in the induction of nutrient transporter surface expression. Consistently, in vitro incubation of blood neutrophils with CF airway fluid does not fully recapitulate this process. Additionally, changes in surface expression of these four nutrient transporters, as observed in vivo, did not appear to be due to changes in intracellular levels of the cognate mRNAs, consistent with the established notion that RNA transcription and protein expression are often asynchronous in neutrophils (3).

Taken together, our data are consistent with a sequential model of neutrophil adaptation to the glucose- and amino acid-rich CF airway milieu. In the first step (blood → A1), neutrophils upregulate surface Glut1 and cytoplasmic vigilin expression, together with mTOR and CREB pathway activation (5). In the second step (A1 → A2), neutrophils further upregulate surface ASCT2, PiT1, and PiT2 and cytoplasmic LC3 expression, along with primary granule exocytosis (4). An alternative model, also compatible with our results, would consider A1 and A2 subsets to be mutually exclusive, rather than sequential adaptive states of CF airway neutrophils (blood → A1 and blood → A2). Both models are presented in Fig. 8.

Further studies are needed to delineate the precise developmental relationships between these distinct neutrophil subsets. Longitudinal studies are also required to determine the potential associations between nutrient transporter expression and the severity of chronic and acute CF airway disease, as well as the effect of treatments. For instance, previous studies suggested that OSs significantly modulate Glut1 expression (38). In the course of the current study, we observed significant alterations in both Glut1 and PiT2 levels following OS treatment. Beyond CF, our findings indicate that the RBD ligands against surface-exposed Glut1, ASCT2, PiT1, and PiT2, and similar ligands derived from the Env of related retroviruses with high affinity for nutrient transporters, are likely to prove useful in investigating mechanisms of metabolic adaptation in response to inflammation and stress.

Acknowledgments
We thank members of the Tirouvanziam Laboratory and V. Tangrieha at Emory University; C. Mongellaz of the Institut de Génétique Moléculaire de Montpellier; L. Obourouglu and members of the Taylor Laboratory; D. Giovannini and members of the Sitbon Laboratory; Y. Gerez, M. Makam, D. Diaz, and members of the Herzenberg Laboratory; the flow cytometry facilities at Emory University and Stanford University; the Montpellier RIO Imaging facility at the Centre National de la Recherche Scientifique/INSERM cluster; and the Production of Recombinant Proteins facility (Centre National de la Recherche Scientifique Montpellier) for support. We also thank J. Denner (Robert Koch Institut, Berlin, Germany) and F.-L. Cosset (Ecole Normale Supérieure, Lyon, France) for sharing KoRV and RD114 env plasmids, respectively, and D. Basiji, T. George, and R. Kong (Aminis) for help with running ImageStreamX analyses.

Disclosures
J.L., J.-L.B., M.S., and R.T. are inventors on a provisional patent describing the use of RBD ligands for cell analysis in human inflammatory diseases (PCT/FR2010/051945 and PCT/EP2011/066231). The other authors have no financial conflicts of interest.

References
10. Barth, A. L., and T. L. Pitt. 1996. The high amino-acid content of sputum from cystic fibrosis patients promotes growth of azototropic Pseudomonas aerugi-


SUPPLEMENTAL TABLE I. Demographic characteristics of the CF patients. Pulmonary function is represented as functional expiratory volume in 1 second (FeV1, % predicted). Ab=Absent, CH=Compound heterozygotes (comprising Delta F508 and a second mutation of the CF gene), F=Female, HO=Delta F508 homozygotes, M=Male, Mu=Mucoid, N/A=Not

<table>
<thead>
<tr>
<th>Gender</th>
<th>Age (years)</th>
<th>CFTR mutations</th>
<th><em>P. aeruginosa</em> infection</th>
<th>FeV1 (% predicted)</th>
<th>Oral steroids</th>
</tr>
</thead>
<tbody>
<tr>
<td>M</td>
<td>22</td>
<td>HO</td>
<td>Mu</td>
<td>68</td>
<td>N</td>
</tr>
<tr>
<td>M</td>
<td>49</td>
<td>HO</td>
<td>Mu</td>
<td>52</td>
<td>N</td>
</tr>
<tr>
<td>F</td>
<td>26</td>
<td>CH</td>
<td>Mu</td>
<td>50</td>
<td>N</td>
</tr>
<tr>
<td>M</td>
<td>11</td>
<td>CH</td>
<td>Mu</td>
<td>56</td>
<td>N</td>
</tr>
<tr>
<td>M</td>
<td>25</td>
<td>HO</td>
<td>Mu</td>
<td>53</td>
<td>Y</td>
</tr>
<tr>
<td>F</td>
<td>50</td>
<td>CH</td>
<td>Ab</td>
<td>67</td>
<td>Y</td>
</tr>
<tr>
<td>F</td>
<td>26</td>
<td>HO</td>
<td>Mu</td>
<td>53</td>
<td>N</td>
</tr>
<tr>
<td>F</td>
<td>50</td>
<td>HO</td>
<td>Mu</td>
<td>34</td>
<td>Y</td>
</tr>
<tr>
<td>F</td>
<td>32</td>
<td>CH</td>
<td>Ab</td>
<td>46</td>
<td>N</td>
</tr>
<tr>
<td>F</td>
<td>45</td>
<td>CH</td>
<td>Ab</td>
<td>57</td>
<td>N</td>
</tr>
<tr>
<td>M</td>
<td>33</td>
<td>OT</td>
<td>Pl</td>
<td>63</td>
<td>N</td>
</tr>
<tr>
<td>F</td>
<td>39</td>
<td>CH</td>
<td>Mu</td>
<td>58</td>
<td>N</td>
</tr>
<tr>
<td>M</td>
<td>32</td>
<td>HO</td>
<td>Mu</td>
<td>81</td>
<td>Y</td>
</tr>
<tr>
<td>F</td>
<td>44</td>
<td>OT</td>
<td>Ab</td>
<td>75</td>
<td>N</td>
</tr>
<tr>
<td>F</td>
<td>12</td>
<td>HO</td>
<td>Ab</td>
<td>56</td>
<td>N</td>
</tr>
<tr>
<td>M</td>
<td>50</td>
<td>HO</td>
<td>Ab</td>
<td>35</td>
<td>N</td>
</tr>
<tr>
<td>M</td>
<td>22</td>
<td>OT</td>
<td>Mu</td>
<td>41</td>
<td>N</td>
</tr>
<tr>
<td>F</td>
<td>22</td>
<td>CH</td>
<td>Mu</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>M</td>
<td>22</td>
<td>CH</td>
<td>Mu</td>
<td>49</td>
<td>N</td>
</tr>
<tr>
<td>F</td>
<td>22</td>
<td>OT</td>
<td>Mu</td>
<td>35</td>
<td>N</td>
</tr>
<tr>
<td>M</td>
<td>30</td>
<td>HO</td>
<td>N/A</td>
<td>75</td>
<td>N/A</td>
</tr>
<tr>
<td>F</td>
<td>23</td>
<td>OT</td>
<td>Ab</td>
<td>67</td>
<td>N/A</td>
</tr>
<tr>
<td>F</td>
<td>22</td>
<td>CH</td>
<td>Ab</td>
<td>62</td>
<td>N/A</td>
</tr>
<tr>
<td>F</td>
<td>39</td>
<td>CH</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

F=14, M=10  31.2 ± 2.4 (mean ± SE)  CH=10, HO=9, Mu=13, Pl=1, Ab=8, N/A=2  56 ± 2.8 (mean ± SE)  Y=3, N=16, N/A=5
available, N=No, OT=Other mutations, Pl=Planktonic, Y=Yes.

**SUPPLEMENTAL TABLE II. Granule exocytosis and nutrient transporter surface expression on in vitro stimulated blood neutrophils.** Cell surface expression of CD63 and CD66b, markers of primary and secondary granule exocytosis, respectively, as well as that of Glut1, ASCT2, PiT1 and PiT2 were assessed on blood neutrophils from healthy control (HC) and CF subjects (N=3 for each group) following 10 minute incubation with LB+fMLF. The median fold change in median fluorescence intensity as compared to unstimulated conditions for each cohort are shown.

<table>
<thead>
<tr>
<th></th>
<th>HC</th>
<th>CF</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD63</td>
<td>29.40</td>
<td>23.74</td>
</tr>
<tr>
<td>CD66b</td>
<td>6.87</td>
<td>5.66</td>
</tr>
<tr>
<td>Glut1</td>
<td>0.79</td>
<td>0.75</td>
</tr>
<tr>
<td>ASCT2</td>
<td>0.83</td>
<td>1.01</td>
</tr>
<tr>
<td>PiT1</td>
<td>1.67</td>
<td>1.41</td>
</tr>
<tr>
<td>PiT2</td>
<td>0.61</td>
<td>0.69</td>
</tr>
</tbody>
</table>
SUPPLEMENTAL FIGURE 1. Flow and image cytometry gating strategies for the analysis of blood and airway neutrophils. (A) Sequential gating based on forward scatter (FSC) and DRAQ5 staining yields live singlets. Leukocytes and neutrophils can be distinguished by their combined side scatter (SSC) and cholera toxin B (CTB) profiles. Flow cytometry analyses of blood and airway neutrophils are shown on the left and right hand panels, respectively. Airway neutrophils can be further subdivided into A1 and A2 subsets (as detailed in references 4, 5). (B) Image cytometry analysis allows separation of live cells as a function of DRAQ5/darkfield profiles. LC3 staining and darkfield intensity facilitates separation of neutrophils (N) from lymphocyte (L), monocyte (M), and eosinophil (E) subsets. Neutrophils are characterized by their scatter properties (brightfield area vs. darkfield intensity plot, assimilated to forward and side scatter, respectively) and lobulated nuclei (DRAQ5 image obtained on ImageStreamX).
SUPPLEMENTAL FIGURE 2. Nutrient transporter mRNA levels in sorted CF blood and airway neutrophils. The level of Glut1, PiT1 and PiT2 transcripts in sorted blood (CD15$^{\text{hi}}$CD16$^{\text{hi}}$) and airway neutrophil subsets (A1: CD15$^{\text{hi}}$CD16$^{\text{hi}}$CD63$^{\text{lo}}$; A2 CD15$^{\text{hi}}$CD16$^{\text{lo}}$CD63$^{\text{hi}}$, N=4, paired with blood samples) from CF patients were assessed by qRT-PCR. Levels were quantified relative to beta-actin (ACTB) and each point represents the calculated delta Ct ($Ct_{\text{Target}} - Ct_{\text{ACTB}}$), with Ct representing the number of cycles required to obtain a signal above background. Undetected transcripts are displayed with a delta Ct above 40 cycles.